title: Optimizing efficacy of quick parathyroid hormone determination in the operating theater.
abstract: The usefulness of intraoperative parathyroid hormone (PTH) monitoring has been extensively documented in primary hyperparathyroidism (HPT), whereas few data have been published on its use in reoperations or in secondary and tertiary HPT. We report our initial experience with a rapid (12 min response) PTH immunochemiluminometric assay performed in the operating room during surgery in 12 patients with primary HPT, 16 end-stage renal disease patients with secondary HPT and five kidney transplanted subjects with tertiary HPT. Blood samples were taken at baseline, within 10 min after resection and subsequently at various intervals whenever needed. The mean PTH levels before and after parathyroidectomy were 230.5 pg/mL (range 69-842) and 47.3 pg/mL (range 5-184), respectively, in primary HPT, 855.0 pg/mL (416-1655) and 202.2 pg/mL (53-440) in secondary HPT, and 205.6 pg/mL (116-301) and 45.4 pg/mL (18-97) in tertiary HPT. All patients but one had a significant percentage decline from pre-excision values (mean 76.9%, 76.0%, and 76.1% in primary, secondary and tertiary HPT, respectively). While a reduction of more than 50% was observed in 30 out of 33 patients after the first intraoperative sampling, additional measurements were performed in 10 cases. On-site PTH monitoring with this user-friendly and reliable system has proved helpful in targeting PTH tests to give the surgeon a rapid and accurate assessment of the intervention. The development of optimal PTH sequence strategies with decision-focused analytical and clinical limits will improve the efficacy of "point-of-care" PTH assay and resource utilization.
authors.affiliation: Laboratory of Clinical Chemistry Baldi e Riberi, San Giovanni Battista Hospital, Turin, Italy. baldiriberi@hotmail.com
authors.forename: G
authors.initials: G
authors.lastname: Mengozzi
authors.forename: C
authors.initials: C
authors.lastname: Baldi
authors.forename: G
authors.initials: G
authors.lastname: Aimo
authors.forename: B
authors.initials: B
authors.lastname: Mullineris
authors.forename: R
authors.initials: R
authors.lastname: Salvo
authors.forename: S
authors.initials: S
authors.lastname: Biasiol
authors.forename: R
authors.initials: R
authors.lastname: Pagni
authors.forename: G
authors.initials: G
authors.lastname: Gasparri
mesh_terms: D000236:Adenoma / Q000097:blood / Q000150:complications / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood* / Q000601:surgery; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000209:etiology / Q000601:surgery; D015592:Immunoradiometric Assay; D007676:Kidney Failure, Chronic / Q000150:complications; D016030:Kidney Transplantation; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D016343:Monitoring, Intraoperative / Q000379:methods*; D009363:Neoplasm Proteins / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood*; D010282:Parathyroid Neoplasms / Q000097:blood / Q000150:complications / Q000601:surgery; D016105:Parathyroidectomy; D012680:Sensitivity and Specificity; D013997:Time Factors
chemical_list: D015415:Biomarkers; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D010281:Parathyroid Hormone